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Introduction. Gastrointestinal complaints are common in patients 
with kidney failure. The aim of this study was to investigate the 
effect of creatinine clearance on Helicobacter pylori (HP) eradication 
rate in patients with peptic ulcer disease.
Materials and Methods. In this clinical trial, 132 patients with a 
range of kidney function (normal to end-stage renal disease) and 
peptic ulcer disease with HP infection were enrolled and divided 
into 5 groups by their creatinine clearance. For all patients, a 14-day 
standard regimen of triple therapy for peptic ulcer was started with 
omeprazole, 20 mg; clarithromycin, 500 mg; and amoxicillin, 1 g; 
twice per day. After 6 weeks, HP eradication rate were evaluated 
and compared between the groups with urea breath test.
Results. The mean age of the participants was 44.84 ± 12.20 years 
and 68 (51.5%) were women. The five groups were not significantly 
different in terms of age, sex distribution, or body mass index. The 
results of urea breath test at 6 weeks were positive in 23 patients 
(17.4%). There was no significant difference in HP eradication rate 
(negative urea breath test) between the five groups.
Conclusions. This study showed no association between the success 
rate of eradication of HP infection and kidney function.
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INTRODUCTION
Gastrointestinal complaints are common in 
patients with kidney failure. In hemodialysis 
patients, pathological changes in the stomach is 
causing a rise in serum gastrin, Helicobacter pylori 
(HP) infection, and delayed emptying of the 
stomach.1 Over the past decade, HP infection has 
progressively declined in developed countries, 
but still is more common in people who have 
immigrated from endemic areas or who had been 
infected during their childhood when HP had 
been common.2
Several factors, including geographical location, 
culture, age, and socioeconomic factors are 
involved in HP infection.2 Although HP infection 
has declined as a result of improvement in health 
status and antibacterial treatments, it was observed 
that a gradual rise coincided with the treatment 
failure rate.3 Antimicrobial resistance, especially 
against clarithromycin is considered the main 
cause of treatment failure of eradication of HP that 
probably was due to the overuse in treatment of 
upper respiratory tract infections.4,5
Helicobacter pylori infection is important in 
forming gastrointestinal lesions; on the other hand, 
high urea levels in the gastric mucosa of patients 
with kidney failure may cause development of HP 
infection for much of the patients. This bacterium 
converts urea to ammonia and raises the local pH 
of the stomach needed for the survival.6 Because of 
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the high potential risk of gastrointestinal mucosal 
lesions in uremic patients and HP colonization, 
screening for and eradicating HP is needed for these 
patients. Bacterial resistance is a great problem in 
the treatment of HP infection; however, treatment is 
challenging since for example, bismuth compounds 
are toxic in uremic patients.7
To our knowledge, there has been no comprehensive 
study about HP eradication rate in patients with 
kidney failure in Iran, and there are a few available 
studies only conducted in hemodialysis patients; 
therefore, we aimed to evaluate the eradication rate 
of HP in patients with a range of kidney function 
from normal to end-stage kidney disease.
MATERIALS AND METHODS
T h i s  c l i n i c a l  t r i a l  w a s  c o n d u c t e d  a f t e r 
approval from the Research Ethics Committee of 
Golestan University of Medical Sciences (Iranian 
Registry of Clinical Trials No, 2013060913609n1). 
Esophagogastroduodenoscopy was done for 1200 
patients with different degrees of kidney function 
to evaluate dyspepsia in the endoscopy division of 
Gorgan 5th Azar Hospital between October 2012 
and November 2013. Gastroscopy was done using 
a videoscope (Olympus GIF-XQ260, Japan). The 
patients with peptic ulcer disease who had recently 
been diagnosed with endoscopy and HP infection 
in their antral samples were confirmed with rapid 
urea test and were selected for the study. Exclusion 
criteria included pregnancy; cancer; liver failure; 
a history of taking nonsteroidal anti-inflammatory 
drugs, proton pomp inhibitors, bismuth, and 
antibiotics during the past 4 weeks; and a history 
of smoking, alcohol, and drug allergy. The patients 
enrolled in this study had not been previously 
treated for HP infection. All participants signed 
an informed consent form.
A total of 150 participants were divided into 
5 groups based on creatinine clearance: group 1, 
creatinine clearance of 90 mL/min and higher; group 
2, creatinine clearance between 60 mL/min and 89 
mL/min; group 3, creatinine clearance between 
30 mL/min and 59 mL/min; group 4, creatinine 
clearance less than 30 mL/min without the need for 
dialysis; group 4, hemodialysis patients. Creatinine 
clearance was measured in 24-hour urine collection 
and calculated as division of serum creatinine 
concentration by urine creatinine concentration, 
multiplied by urine volume.
For all of the patients, the standard 14-day 
regimen of three drugs was started, including 
20 mg of omeprazole, 500 mg of clarithromycin, 
and 1000 mg of amoxicillin, twice a day. In cases 
where creatinine clearance was below 30 mL/
min, the doses of clarithromycin and amoxicillin 
were reduced by 50%. Creatinine clearance was 
monitored for 3 months before the start of the study 
and during the study to ensure that it remained 
constant. A urea breath test (UBT) was done using 
a 13C-UBT device (HeliArobe kit, Kibion, Uppsala, 
Sweden) for eradication assessment 6 weeks after 
completion of the treatment.
The collected data were analyzed using the 
SPSS software (Statistical Package for the Social 
Sciences, version 19.0, SPSS Inc, Chicago, Ill, 
USA). Comparisons were done using the 1-way 
analysis of variance test, and the chi-square and 
Fisher exact tests for continuous and categorical 
variables, respectively. A P value less than .05 was 
considered significant.
RESULTS
Eighteen patients did not return for follow-up 
and 132 patients were remained in the analysis. 
The mean age of the patients was 44.84 ± 12.20 
years and 51.5% (n = 68) of them were women. 
Body mass index was less than normal in 9.8% 
of the patients and normal in 34.8%, while 43.9% 
were overweight and 11.4% were obese. All of the 
patients had HP infection and different levels of 
kidney function. The Table shows the distribution 
Study Groups
Parameter 1 2 3 4 5 All P
Number of patients 26 27 26 27 26 132 …
Mean age, y 45.30 ± 12.38 45.74 ± 13.62 45.30 ± 10.95 42.07 ± 10.85 45.84 ± 13.46 44.84 ± 12.20 .67
Sex
Male 13 14 12 12 17 68
Female 13 13 15 14 9 64 .98
Mean body mass index, kg/m2 25.23 ± 4.22 25.10 ± 4.13 24.36 ± 4.12 25.56 ± 3.49 24.98 ± 5.10 25.05 ± 4.19 .26
Demographic Data of Participants
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of the patients in groups 1 to 5 (normal kidney 
function to dialysis dependence). The differences 
between the study groups were not significant in 
terms of age, sex, and body mass index (Table).
The result of UBT 6 weeks after treatment was 
negative in 109 (82.6%) patients, while it was positive 
for 23 (17.4%). There was significant difference 
between the HP eradication rate (according to the 
result of UBT at 6 weeks) between the five groups 
(P = .99; Figure).
DISCUSSION
Findings of this study did not show a significant 
relationship between creatinine clearance and 
eradication of HP infection in the studied patients. 
According to some factors affecting the disease 
process, this can be justified. These findings can 
be attributed to the prevalence of peptic ulcer and 
HP infection in different populations. Peptic ulcer 
is more common in patients with kidney failure 
compared with healthy population, which could 
be due to various causes, including increased 
gastrin and gastric acid secretion, increased 
parathyroid hormone, and decreased mucosal 
resistance. However, the prevalence of HP infection 
is varying between different studies. Some studies 
have reported the prevalence of HP infection in 
patients with renal impairment similar to normal 
population.8,9 A study in Iran also showed that the 
prevalence of HP infection is similar in patients 
with and without chronic kidney failure.10 In other 
studies, the prevalence of HP infection in patients 
with impaired kidney function is less than in the 
normal population, which rises the hypothesis of 
the protective role of high concentrations of urea 
or acid-reducing medications and antibiotics.11,12
There is not enough information about the 
effects of factors such as age, sex, race, and body 
mass index on the prevalence of HP infection and 
response to eradication therapy in patients with 
kidney failure. In this study, the response to HP 
eradication therapy among the study groups was 
not associated with these variables. However, based 
on various studies, in Iran and other countries, the 
average age of patients with HP infection is between 
40 and 60 years,13,14 and the rate of colonization with 
bacteria increases from childhood to the age above 
60 years.15 Also, HP infection is more common in 
men,16,17 while some other studies have reported 
a higher prevalence in women.18,19
On the other hand, because of removing bismuth 
from HP eradication regimens for renal toxicity, 
response to eradication therapy in this study may 
not be comparable to the expected rates based on 
other observations,20 while some other studies have 
reported a better eradication rate with the regimens 
without bismuth than the standard regimen.21,22 
Also, the substantially increased antibiotic resistance 
to clarithromycin in the world in recent years, in 
particular of the HP infection, is likely to distort 
the results.23,24
In addition to the above factors, the diagnostic 
accuracy of UBT to assess eradication of HP 
infection is also an important confounding factor 
in the study. Calvet and colleagues found that UBT 
has a sensitivity of 75% and a specificity of 60%, 
but with the change in the diagnostic threshold, 
the sensitivity and specificity increased to 90%.25 
In Peng and colleagues’ study, the sensitivity and 
specificity of UBT for HP were reported 100% 
Results of urea breath test 6 weeks after treatment.
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and 85.1%, respectively.26 Kawai and colleagues 
reported a sensitivity and a specificity 97% and 
100%, respectively.27 Despite several studies on 
the accuracy of UBT, few studies have conducted 
on the diagnostic accuracy of this test in patients 
with kidney dysfunction. Lopez and colleagues 
determined a sensitivity and a specificity of 94% 
and 96%, respectively, for diagnosis of HP infection 
in hemodialysis patients.28 Nardone and colleague’s 
study showed the diagnostic accuracy of UBT did 
not decrease in patients with uremia, and therefore, 
it was a useful method for the diagnosis of HP 
infection.29
Researchers have reported different results of the 
eradicating HP infection and creatinine clearance 
using various treatment regimens and methods. 
In contrast to our findings, Itatsu and colleagues 
showed that low-dose regimen of 7 days of 
lansoprazole, amoxicillin, and clarithromycin was 
safe and effective in the treatment of HP infection 
in hemodialysis patients.30 Mak and associates 
concluded that short-term 3-drug treatment in 
patients with kidney failure was substantially 
effective.31 Sheu and colleague’s study showed 
the 3-drug regimen containing clarithromycin 
and metronidazole without amoxicillin was more 
effective in patients with kidney failure.32 Two 
other studies also obtained similar results to the 
above studies.33,34 In contrast, the study of Tsukada 
and coworkers showed the 3-drug regimen of 
omeprazole, amoxicillin, and clarithromycin 
were effective in both hemodialysis patients 
and general population, and eradication of HP 
was not significantly difference between the two 
groups.35 Moreover, Seyyedmajidi and colleagues 
obtained similar results in their study and reported 
comparable response to HP eradication therapy in 
patients with kidney failure to the control group.36
Given the findings of this study showed no 
significant difference in responses to the eradicating 
HP infection among patients with kidney failure 
and those with normal kidney function, it can be 
inferred that uremia is not a factor in response to 
HP eradication therapy. Since hypergastrinemia 
causes ammonium increase in gastric juice and 
reducing gastric pH and thereby plays a role in the 
pathogenesis of peptic ulcer disease, some studies 
have suggested that eradication of HP infection by 
lowering serum gastrin in hemodialysis patients 
may reduce the incidence of peptic ulcer disease.37,38
Although this study has assessed only an initial 
response to HP infection in patients with renal 
impairment compared to normal population and 
has not evaluated the recurrence rate of peptic 
ulcer after eradication of HP and adverse effects of 
regimen, the 2-year study of Tseng and colleagues 
showed that relapse rates in patients with ESRD 
were significantly higher than nonuremic patients.39 
Additionally, initial treatment response, relapse 
rate, and the rate of treatment failure due to drug 
side effects are important in evaluating eradication 
of HP in uremic patients.
CONCLUSIONS
Our results showed no significant relationship 
between eradication of HP infection and kidney 
function. It can be concluded that renal impairment 
has not a significant effect on the response to 
eradicating HP infection, and it seems there are 
not much differences between uremic patients and 
the general population. However, to confirm our 
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